Shardul Amarchand Mangaldas Advises Eris Life Sciences on Acquisition of India Business of Strides Shasun

Manish Arya / On 2017-11-22 15:25:26

Shardul Amarchand Mangaldas advised Eris Lifesciences Limited in relation to acquisition of India business of Strides Shasun Limited, including acquisition of 100% stake in Strides Healthcare Private Limited. As a part of the transaction, Eris Lifesciences Limited would acquire the domestic branded generics business of Strides Shasun Limited through a business transfer of the Undertaking from Strides Shasun Limited, and acquisition of 100% shares of Strides Healthcare Private Limited in which certain brands of the Undertaking are housed.

The transaction team was led by Mr. Amit Khansaheb and Mr. Roshan Thomas, Partners; and included Mr. Prateek Lala, Senior Associate; Mr. Hardik Bhatia, Senior Associate; Ms. Alekhya Donepudi, Associate; Mr. Christopher Rao, Associate and Ms. Rimjhim Khandelwal, Associate.

The parties involved in the transaction were Eris Lifesciences Limited (our client); Strides Shasun Limited (counterparty); and Strides Healthcare Private Limited (counterparty).

Other advisors to the transaction were Ernst & Young (investment advisor for Eris Lifesciences Limited); MAPE Advisory Group (acted as investment advisor) and Tatva Legal (acted as legal advisor for Strides Shasun Limited).

The deal was signed on November 18, 2017 and is expected to close by November 30, 2017 (subject to completion of customary conditions precedent)

Related Stories